Transcriptome-wide Mendelian Randomization During CD4+ T Cell Activation Reveals Immune-Related Drug Targets for Cardiometabolic Diseases

Xueyan Wu,Hui Ying,Qianqian Yang,Qian Yang,Haoyu Liu,Yilan Ding,Huiling Zhao,Zhihe Chen,Ruizhi Zheng,Hong Lin,Shuangyuan Wang,Mian Li,Tiange Wang,Zhiyun Zhao,Min Xu,Yuhong Chen,Yu Xu,Emma E Vincent,Maria Carolina Borges,Tom R Gaunt,Guang Ning,Weiqing Wang,Yufang Bi,Jie Zheng,Jieli Lu
DOI: https://doi.org/10.1038/s41467-024-53621-7
IF: 16.6
2024-01-01
Nature Communications
Abstract:Immunity has shown potentials in informing drug development for cardiometabolic diseases, such as type 2 diabetes (T2D) and coronary artery disease (CAD). Here, we performed a transcriptome-wide Mendelian randomization (MR) study to estimate the putative causal effects of 11,021 gene expression profiles during CD4+ T cells activation on the development of T2D and CAD. Robust MR and colocalization evidence was observed for 162 genes altering T2D risk and 80 genes altering CAD risk, with 12% and 16% respectively demonstrating CD4+ T cell specificity. We observed temporal causal patterns during T cell activation in 69 gene-T2D pairs and 34 gene-CAD pairs. These genes were eight times more likely to show robust genetic evidence. We further identified 25 genes that were targets for drugs under clinical investigation, including LIPA and GCK. This study provides evidence to support immune-to-metabolic disease connections, and prioritises immune-mediated drug targets for cardiometabolic diseases.
What problem does this paper attempt to address?